Author: Kim, Sae-Hae; Cho, Byeol-Hee; Lee, Kyung-Yeol; Jang, Yong-Suk
Title: N-terminal Domain of the Spike Protein of Porcine Epidemic Diarrhea Virus as a New Candidate Molecule for a Mucosal Vaccine Document date: 2018_6_15
ID: 4vx7ez7s_1
Snippet: Porcine epidemic diarrhea virus (PEDV), a causative agent of PED, was first described as a devastating enteric disease of pigs in the United Kingdom in 1971 (1) . PEDV is a member of the Alphacoronavirus genus that has a single-stranded positive-sense RNA genome (2) . PEDV infection induces diarrhea, causing high mortality in suckling piglets and weight loss in older hogs, which have led to significant economic losses in the swine industry (3) . .....
Document: Porcine epidemic diarrhea virus (PEDV), a causative agent of PED, was first described as a devastating enteric disease of pigs in the United Kingdom in 1971 (1) . PEDV is a member of the Alphacoronavirus genus that has a single-stranded positive-sense RNA genome (2) . PEDV infection induces diarrhea, causing high mortality in suckling piglets and weight loss in older hogs, which have led to significant economic losses in the swine industry (3) . The PEDV genome consists of seven open reading frames encoding four structural proteins, the spike (S) glycoprotein, membrane protein, envelope protein, and nucleocapsid protein (4) . Among the structural proteins, the S glycoprotein consists of the S1 and S2 domains. The C-terminal domain (CTD) of the S1 protein has been considered a major target Ag inducing neutralizing Ab production, because it interacts with aminopeptidase N (APN), a functional receptor involved in PEDV infection, on the host cell membrane (5) . Based on the observation that PEDV infection occurs mainly in epithelial cells of the small intestine via the fecal-oral route, and gross lesions are detected in the gastrointestinal tract of PEDV-infected animals, the establishment of mucosal immunity is required to induce protective immunity against PEDV infection (6, 7) . However, a mucosal PEDV vaccine is not available, and inducing mucosal immunity is difficult with current PEDV vaccine materials, which are administered intramuscularly, because the gut mucosa has a unique immune system, into which Ags enter only from the intestinal lumen due to the lack of afferent lymphatic vessels in mucosal immune-inductive site, compared with that of the systemic immune system. Interestingly, recent reports suggest that the N-terminal domain (NTD) of S protein also interacts with 5-N-acetylneuraminic acid, a possible sugar co-receptor, expressed on epithelial cells and aids in PEDV infection in the host (8) . Consequently, use of the NTD as a mucosal vaccine material is a plausible vaccination strategy to protect against PEDV infection.
Search related documents:
Co phrase search for related documents- acetylneuraminic acid and mucosal vaccine: 1
- causative agent and mucosal PEDV vaccine: 1
- causative agent and mucosal vaccine: 1, 2
- diarrhea virus and mucosal PEDV vaccine: 1, 2, 3, 4, 5, 6, 7, 8
- diarrhea virus and mucosal vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- enteric disease and mucosal vaccine: 1, 2
- envelope protein and mucosal vaccine: 1, 2, 3, 4, 5
- epithelial cell and mucosal vaccine: 1
- fecal oral route and mucosal PEDV vaccine: 1
- fecal oral route and mucosal vaccine: 1
- gastrointestinal tract and mucosal PEDV vaccine: 1, 2
- gastrointestinal tract and mucosal vaccine: 1, 2, 3, 4, 5, 6, 7, 8
- gut mucosa and mucosal vaccine: 1
- high mortality and mucosal vaccine: 1, 2, 3
- host cell and mucosal vaccine: 1
- immune system and mucosal vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- membrane protein and mucosal vaccine: 1, 2, 3, 4, 5
Co phrase search for related documents, hyperlinks ordered by date